Governance
Investors

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

Innovating targeting

Philogen is a Swiss-Italian biotechnology company, founded in 1996 and listed on the Italian Stock Exchange, with a mission to innovate the treatment of cancer and other serious conditions

 

Oct 01 2024
, ,

Philogen is pleased to invite you to a new webinar on October 1, 2024, at 15:00 GMT | 16:00 CET.

Management will present the financial results and provide an update on the industrial programs. Please contact us at IR@philogen.com or follow the link to register to...
Oct 01 2024
, ,

Sun Pharma e Philogen stipulano un accordo di commercializzazione, licenza e fornitura in esclusiva per la commercializzazione del prodotto innovativo FIBROMUN a livello mondiale.

more details
Oct 01 2024
, ,

Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN

more details
Sep 27 2024
, ,

Philogen to attend the European Association of Nuclear Medicine (EANM) annual meeting on October 19-23, 2024

Andrea Galbiati is giving a presentation about Philochem’s FAP-targeted radioligand therapeutics on October 20 (session 604), entitled “Development of Multivalent...
Sep 25 2024
, ,

Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2024 (Price sensitive)

more details
Sep 25 2024
, ,

The Board of Directors Approves the Half-Yearly Financial Report at 30 June 2024 (Price sensitive) – Courtesy English Translation

more details
Sep 04 2024
, ,

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry....
Jul 16 2024
, ,

Philogen to attend PEGS2024 on September 6, 2024 in Barcelona

Prof. Dr. Dario Neri, Philogen’s CEO and CSO, is giving a lecture entitled "Antibody-Cytokine Fusion Proteins for Cancer Therapy: Late-Stage Clinical Results" Dr....
Jul 09 2024
, , ,

Philogen is pleased to invite you to a new webinar on July 10, 2024, at 14:00 GMT | 15:00 CET.

Management will provide an update on the industrial programs, including on the topline results from the Nidlegy™ Phase III trial presented at ASCO 2024. Please contact...
Jul 04 2024
, ,

Submission of NidlegyTM Marketing Authorization Application Validated by EMA

For more details

OUR SCIENCES

Learn about our strategy

PIPELINE

Learn more about our pipeline

WORK WITH US

Look at open positions